RAF inhibitors that evade paradoxical MAPK pathway activation.

Area of Science:

• Oncology
• Molecular Biology
• Pharmacology

Background:

• Oncogenic BRAF mutations drive cancer via the MAPK pathway, leading to targeted therapies like RAF inhibitors for melanoma.
• First-generation RAF inhibitors can paradoxically activate the MAPK pathway, stimulating growth in certain cancers, particularly those with upstream RAS or receptor tyrosine kinase activation.
• This paradoxical activation presents a significant challenge in cancer treatment, limiting efficacy and durability.

Purpose of the Study:

• To identify and characterize next-generation RAF inhibitors, termed 'paradox breakers,' that selectively inhibit mutant BRAF without paradoxical MAPK pathway activation.
• To evaluate the efficacy of these paradox breakers in preclinical models of cancer, including those resistant to first-generation RAF inhibitors.
• To assess the potential of paradox breakers to overcome resistance mechanisms and improve safety and durability of RAF inhibitor therapy.

Main Methods:

• Development and screening of novel ATP-competitive RAF inhibitors.
• In vitro and in vivo testing of RAF inhibitors in cancer cell lines and xenograft models with BRAF or upstream mutations.
• Analysis of MAPK pathway signaling, cell proliferation, and gene expression in response to RAF inhibitors.
• Evaluation of resistance mechanisms to first-generation RAF inhibitors and assessment of paradox breaker efficacy in overcoming them.

Main Results:

• Next-generation RAF inhibitors (PLX7904, PLX8394) suppressed mutant BRAF cancer cells without paradoxical MAPK pathway activation.
• Unlike vemurafenib, paradox breakers did not stimulate growth or induce MAPK pathway response genes in cells with HRAS mutations.
• Paradox breakers demonstrated efficacy in overcoming known resistance mechanisms to first-generation RAF inhibitors.

Conclusions:

• Next-generation RAF inhibitors ('paradox breakers') offer a promising therapeutic strategy by dissociating MAPK pathway inhibition from paradoxical activation.
• These agents have the potential for improved safety and more durable efficacy compared to first-generation RAF inhibitors.
• Clinical evaluation of PLX8394 is underway, suggesting a potential paradigm shift in RAF inhibitor therapy.